IPO Market Shows Signs of Life as Acelyrin Begins Nasdaq Bid

California-based Acelyrin filed an initial public offering (IPO) Thursday in an effort to advance its immunology programs through the clinic.

The privately held biotech has yet to disclose how many shares of its common stock it plans to put up for sale or how much it expects to collect in net proceeds. A Filing Fee Table included in its SEC filing shows that Acelyrin could be aiming for a $100 million IPO, though this figure is subject to change.